With Merck's Zilmax out of the picture, Eli Lilly drug surges

Now that Merck's ($MRK) Zilmax feed additive is off the market for a safety study, Eli Lilly's ($LLY) competing drug Optaflexx has seen a surge in demand that may have outstripped its ability to supply it immediately. Lilly's Elanco unit says its supply isn't short, but it's "managing the supply" as it assesses long-term demand. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.